Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Лечение рака молочной железы завершено, а сон не вернулся: новые возможности смартфона проверят у 747 женщин
Услышать одышку недостаточно: зачем в новом исследовании к экстренным звонкам добавляют видео со смартфона
Что может рассказать выдох: новый тест проверят на 1000 пациентах с подозрением на рак ЖКТ
До первых проблем с памятью: Roche проверит препарат у людей с биомаркерами болезни Альцгеймера
A Diaper Photo Could Help Spot Liver Disease in Babies: UK Tests AI
После лечения опухоль осталась: новую комбинацию проверят у 1000 пациентов с агрессивным раком груди
Лечение ВИЧ без ежедневных таблеток: Gilead проверит новую длительную схему в двух исследованиях фазы 3

Предстоящие клинические испытания

Clinical Research Jobs

More jobs

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться